Expand ROIV Menu
ROIV MENU

ROIV Latest Press Releases

-- May 20, 2026 --

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update Globe Newswire 7:00 AM

-- May 11, 2026 --

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026 Globe Newswire 4:05 PM
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026 Globe Newswire 4:05 PM

-- April 2, 2026 --

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) Globe Newswire 5:00 AM
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) Globe Newswire 5:00 AM

-- March 28, 2026 --

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis Globe Newswire 3:00 PM

-- March 3, 2026 --

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna Globe Newswire 4:15 PM
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna Globe Newswire 4:15 PM
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis Globe Newswire 7:00 AM

-- February 6, 2026 --

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) Globe Newswire 7:00 AM
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 Globe Newswire 7:00 AM
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Globe Newswire 7:00 AM

-- January 23, 2026 --

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 Globe Newswire 5:25 PM
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 Globe Newswire 4:15 PM
Market Data Delayed 15 Minutes